Beigene Ltd ADR (ONC) Stock Price, Quote & News

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multic...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 61 685 19 00

Website: beonemedicines.com

Address:

94 Aeschengraben 27, Basel, Switzerland

PrivateTrading Jun. 12 at 8:05 PM

$ONC Recent share price weakness may be attributed to RSUs that were exercised by executives at the company.

0 · Reply

PrivateTrading Jun. 11 at 3:29 PM

$ONC The company has plenty of cash The share price is low Opportunity for the company to support the stock Q. Given that the FDA approved Calquence + venclexta fixed duration in Feb. 2026, why is Brukinsa + Sonrotoclax fixed duration two years behind the competitor?

0 · Reply

DaSqueeza Jun. 8 at 7:37 PM

$ONC is also 20x more expensive than $NRIX

1 · Reply

MaxDanger Jun. 8 at 7:27 PM

$NRIX I like this deal with $RHHBY. It gives the company over a billion in cash, significantly reduces its burn rate by via shared development expenses with roche. Allows them to put money into other assets and speed up development of those products. This is a game changer for the company, removes the risk of dilution for years to come, and increases the speed of development for the rest of their portfolio. $ONC is a bit ahead of them in the degrader space but this deal will level the playing field and allow for additional trials. The only surprise here is that it wasn’t a deal with a $AZN.

0 · Reply

Estimize Jun. 8 at 11:03 AM

Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont

0 · Reply

Pika_Capital Jun. 5 at 2:14 PM

$ONC I'm buying more here

0 · Reply

MarketBeat Jun. 2 at 6:11 AM

https://marketbeat.com/a/8686887/ $ONC BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

0 · Reply

BillionerOfKing Jun. 2 at 4:07 AM

$ONC Current Stock Price: $279.79 Contracts to trade: $280.0 ONC Jun 18 2026 Call Entry: $8.90 Exit: $14.19 ROI: 59% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

jmcekc May. 28 at 8:59 PM

$ONC What gives here!? Thought we would be popping. Instead it’s pooping.

0 · Reply

topstockalerts May. 28 at 8:45 PM

J.P. Morgan reinstated coverage on 14 large-cap biotech companies, saying the sector is nearing a major inflection point as strong drug pipelines increasingly translate into profitable and diversified businesses. The bank noted many biotech firms are approaching sustained profitability, supported by expanding product portfolios, improving margins, and upcoming clinical catalysts. The firm assigned Overweight ratings to Vertex Pharmaceuticals, Alnylam Pharmaceuticals, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis Pharmaceuticals, BioMarin Pharmaceutical, and Mirum Pharmaceuticals. Neutral ratings were maintained on BioNTech, Incyte, and Halozyme Therapeutics, while Moderna received an Underweight rating. J.P. Morgan highlighted Vertex’s expansion beyond cystic fibrosis, Alnylam’s strong Amvuttra growth, and continued momentum for BeOne Medicines and United Therapeutics. $VRTX $ALNY $ONC $UTHR $INSM

0 · Reply

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Jun 12, 2026, 6:00 AM EDT - 3 days ago

Market Cap	23.65B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	318.72
Profit Margin	-16.92%
Debt to Equity Ratio	0.05

Volume	189,200
Avg Vol	468,388
Day's Range	N/A - N/A
Shares Out	99.25M
Stochastic %K	82%
Beta	0.35
Analysts	Strong Sell
Price Target	$321.39